Table 3 Reasons for discontinuing RPV or EFV
From: Observational cohort study of rilpivirine (RPV) utilization in Europe
RPV1 N (%) | EFV2 N (%) | |
|---|---|---|
Median (IQR) duration of treatment at discontinuation (Months) | 18.2 (6.7–34.2) | 9.8 (3.4–23.1) |
Treatment failure (virological, immunological, and/or clinical) | 29 (5.8) | 14 (9.5) |
Toxicity | 73 (14.7) | 45 (30.4) |
Predominantly from central nervous system (CNS) | 13 (2.6) | 33 (22.3) |
Predominantly from kidneys | 20 (4.0) | 4 (2.7) |
Liver | 6 (1.2) | 3 (2.0) |
Hypersensitivity reaction (skin eruption etc.) | 3 (0.6) | 2 (1.4) |
Predominantly from abdomen/GI tract | 13 (2.6) | 1 (0.7) |
Abnormal fat redistribution | 2 (0.4) | 0 (0.0) |
Cardiovascular disease | 2 (0.4) | 0 (0.0) |
Dyslipidaemia | 0 (0.0) | 1 (0.7) |
Other side effects–not specified | 14 (2.8) | 1 (0.7) |
Other | ||
Physician's decision, not specified | 167 (33.5) | 23 (15.5) |
Participant's wish/decision, not specified | 38 (7.6) | 18 (12.2) |
Availability of more effective treatment (not specifically failure or side effect related) | 15 (3.0) | 5 (3.4) |
Structured Treatment Interruption (STI) | 3 (0.6) | 0 (0.0) |
Enrolled in RCTs | 2 (0.4) | 0 (0.0) |
Other causes, not specified | 91 (18.3) | 23 (15.5) |
Unknown | 80 (16.1) | 20 (13.5) |